The 8th Annual Symposium in Translational Research in Pathology

Friday, April 19, 2024, 1:00 PM - 7:00 PM, Zuckerman Research Center, 417 East 68th Street, New York , NY

The Gerald Award lecture is presented as part of our annual Symposium in Translational Research in Pathology, which also features research presentations and a poster session from members of the MSK Pathology and Laboratory Medicine Department. This Symposium is designed to highlight new advances in the field of translational research as it relates to pathology. 

The Memorial Sloan Kettering Cancer Center William L. Gerald Award is conferred on a pathologist whose recent innovative research has provided novel insights into cancer biology and whose career trajectory suggests the potential for outstanding contributions in the years to come.

The award reflects the contributions and values brought to the Department of Pathology by William L. Gerald, an Attending Pathologist at MSK from 1992 to 2008. A gifted morphologist, Dr. Gerald was committed to providing state-of-the-art patient care as a surgical pathologist and recognized that the molecular characterization of human neoplasms could affect the classification, prognostic assessment, and treatment of cancer. Dr. Gerald had broad diagnostic expertise but focused his clinical work on genitourinary pathology, and he was also the pediatric pathology consultant for the department. He was a pioneer in the molecular characterization of cancer at a time when now commonplace molecular techniques were still cutting-edge technology.

Dr. Gerald provided the first histologic description and subsequent molecular characterization of desmoplastic small round cell tumor, an entity that now bears his name. His work helped establish a novel molecular classification of neuroblastoma. He used gene expression analysis and other molecular assays to develop the prognostic characterization of prostate cancer.

Throughout his career, Dr. Gerald collaborated with and provided mentorship to numerous trainees and colleagues. His quiet good nature and thoughtful approach made him a model physician-scientist. He was approachable and always willing to provide key insights. This award is a tribute to his scientific contributions and personal attributes, and to the legacy he left behind.

Target Audience

This Symposium is directed toward practicing pathologists and research scientists, both in academic and private practice environments, as well as residents and fellows in pathology, who wish to broaden their understanding of neoplastic diseases.

1. Provide an overview of the latest developments in translational research in pathology
2. Create awareness of current methodological approaches to understand disease
3. Apply updated approaches to diagnosis of disease

This symposium is complimentary for all to attend. Please complete registration through the 'Register' tab above in order to attend (registration is required).

This symposium offers participants the choice of attending either in person or virtually. In-person attendees should contact [email protected] at least one week prior to the symposium if you have any special dietary requests or require any specific accommodations.

If you are registered for this symposium and unable to attend, please email [email protected] to cancel your registration.

Please note that employees who are currently employed by a Pharmaceutical and Medical Device company may attend MSK CME activities for their own education. Marketing, sales, and promotion of products and services is strictly prohibited at MSK CME activities. For more information, please visit our Help page.

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABPath CC Recognition Statement

This activity will offer 1.50 Lifelong Learning (CME) credit towards the American Board of Pathology’s Continuing Certification program.

Hotel Accommodations

We look forward to welcoming you to Memorial Sloan Kettering for this program. If you’ll be traveling to New York City from out of town, we recommend that you plan your overnight stays as soon as possible. To make the planning a little easier, Memorial Sloan Kettering has negotiated special rates and amenities at select hotels in Manhattan. To view the list of select hotels and additional details on each, please visit: msk.org/accommodations

Parking Information

Street parking in Manhattan is extremely limited, so you may find it more convenient to park in Memorial Sloan Kettering’s garage or in a commercial garage. For a list of parking resources around MSK, click here. Please note that MSK CME does not offer parking validation for course attendees.

MSK Course Directors 

Hikmat A. Al-Ahmadie, MD
Attending, Genitourinary Pathology

Lora Hedrick Ellenson, MD
Director, Gynecologic Pathology

Meera R. Hameed, MD
Chief, Surgical Pathology Service

Natasha Rekhtman, MD, PhD
Attending Pathologist

 

MSK Leadership Welcome

Kojo S.J. Elenitoba-Johnson, MD
Chair, Department of Pathology and Laboratory Medicine
James Ewing Alumni Chair of Pathology

 

William L. Gerald Awardee & Lecturer

Jorge S. Reis-Filho, MD, PhD, FRCPath
Vice President, Cancer Biomarker Development
AstraZeneca
Gaithersburg, MD

 

MSK Department of Pathology & Laboratory Medicine Faculty 

 

MSK Department of Pathology & Laboratory Medicine Fellows

Susan Armstrong, MD, PhD
Elisabet Pujadas, MD, PhD
Theodore Vougiouklakis, MD

Mitigation of Relevant Financial Relationships

Memorial Sloan Kettering Cancer Center adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.